Safety signals have sparked vital discussions on patient access to ATMPs, marking a pivotal moment i...
Read moreNew website provides regular updates on NLF's work, addresses challenges, and showcases collaboratio...
Read moreThe World Evidence, Pricing, and Access (EPA) Congress stands as Europe’s premier event in mar...
Read moreProposed changes in Germany's pharma strategy suggest replacing publicly listed AMNOG rebates with c...
Read moreThe Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has implemented the Interna...
Read moreOur experts provide an overview of the five key trends that could shape the pricing and market acces...
Read moreBack in January this year, we summarised the key trends our market access experts believed would dom...
Read moreThe statutory scheme has been updated with new percentages for 2024-2026, and has received backlash ...
Read moreGermany’s Health minister has announced that publicly listed AMNOG rebates could be replaced by co...
Read moreAIFA reform is a landmark change which propels Italy towards expedited drug approvals and improved a...
Read more